Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib 150 mg versus 300 mg in progressive or symptomatic medullary thyroid carcinoma
NL-OMON37338Phase 4Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vandetanib in Medullary Thyroid Cancer (MTC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Objective response rate and Likely range of response rates by starting dose. Started Aug 2012; status: active, not recruiting.
02
Drugs
vandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON37338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37338.